1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Hester Biosciences Limited

Hester Biosciences Limited

HESTERBIO.BO
Hester Biosciences LimitedIN flagBombay Stock Exchange
1,940.00
INR
-82.15
- -
16.50BMarket Cap
Hester Biosciences Limited
HESTERBIO.BO
(Bombay Stock Exchange)

Recent

price

1,940.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
53.9
57.02
90.33
81.17
105.84
118.37
144.72
159.8
209.32
215.44
251.95
276.25
312.8
358
383.56
- -
404.48
Revenue per Share
- -
8.99
12.85
11.11
15.98
22.57
27.68
30.12
48.86
34.29
40.47
46.22
31.3
22.2
33.89
- -
67.66
Basic EPS, GAAP
-8.05
4.07
-19.17
-4.4
1.07
22.16
40.91
44.7
54.91
43.23
68.24
10.24
27.74
56.64
79.54
- -
- -
Free Cash Flow per Basic Share
1.9
2.15
0.79
2
2
6.1
4.93
7.58
12.06
8.44
6.6
10
10
8.06
6.37
- -
- -
Dividend per Share
6.67
24.01
38.75
38.67
43.15
60.83
79.93
95.69
132.22
157.2
191.16
227.25
248.68
262.84
302.79
- -
10.35
Book Value per Share
61.43
72.03
94.93
89.57
102.86
125.56
147.92
169.69
212.39
242.28
276.37
311.92
335.74
351.41
394.53
- -
435.45
Tangible Book Value per Share
8
8
7
9
9
9
9
9
9
9
9
9
9
9
8
- -
8
Basic Weighted Avg Shares
420
483
651
690
900
1,007
1,231
1,359
1,781
1,833
2,143
2,350
2,661
3,045
3,111
3,326
3,326
Sales/Revenue/Turnover
-2.17
30.07
26.89
28.1
22.16
28.24
28.76
29.11
35.09
25.1
27.42
24.03
15.62
13.88
14.22
20.38
20.38
Operating Margin (%)
45
41
44
54
55
58
70
97
118
132
133
166
207
172
168
189
189
Depreciation Expense
- -
76
93
95
136
192
235
256
416
292
344
393
266
189
275
556
556
Net Income, GAAP
39.45
37.07
37.04
31.44
26.47
22.68
26.34
36.14
28.43
24.98
30.75
26.2
30.18
33.76
27.15
24.2
24.2
Effective Tax Rate (%)
- -
15.76
14.22
13.69
15.1
19.06
19.13
18.85
23.34
15.92
16.06
16.73
10.01
6.2
8.84
16.73
16.73
Profit Margin (%)
301
179
109
116
250
371
420
438
930
758
1,001
979
789
1,091
700
561
561
Working Capital
213
13
137
155
318
331
446
365
584
817
880
1,698
1,905
1,874
1,388
963
963
LT Debt
480
611
685
763
878
1,075
1,265
1,450
1,812
2,065
2,360
2,674
2,885
3,029
3,267
3,678
3,678
Total Equity
-0.85
12.65
12.72
12.1
11.23
14.28
14.36
12.33
18.41
11.44
11.89
9.82
5.45
5
5.89
9.26
9.07
Return on Invested Capital (%)
5.83
30.29
19.58
17.39
19.85
21.15
20.97
20.86
25.65
13.64
14.07
11.58
6.24
4.65
7.45
18.2
27.83
Return on Capital (%)
0.01
59.63
38.37
31.08
39.07
43.4
39.33
34.3
42.88
23.7
23.24
22.09
13.15
8.68
11.72
43.79
654.03
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
943
- -
985
LT Borrowings
1,136
- -
900
LT Finance Leases
57
- -
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
- -
9
Market Capitalization
15,355
12,643
10,383

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,037
- -
2,086
Cash, Cash Equivalents & STI
282
- -
275
Accounts Receivable, Net
926
- -
954
Inventories
659
- -
725
Total Current Liabilities
1,414
- -
1,525
Payables & Accruals
- -
- -
- -
ST Debt
943
- -
985
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.21%
9.33%
12.59%
Free Cash Flow
37.67%
44.67%
-0.57%
Net Income, GAAP
18.27%
20.16%
102.41%
Sales/Revenue/Turnover
12.99%
9.28%
6.91%
Total Cash Common Dividend
- -
- -
16.6%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
879
705
670
793
3,045
2025
823
837
632
819
3,111
2026
841
710
774
1,001
3,326

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.89
4.8
4.73
- -
22.2
2025
8.8
9.86
13.41
1.82
33.89
2026
20.33
16.85
10.94
19.45
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
8.06
2025
- -
- -
- -
- -
6.37
2026
- -
- -
- -
- -
- -
Similar Companies
Curaleaf Holdings, Inc. (CURA.CN)
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
Yuyu Pharma, Inc. (000225.KS)
FutureWorld Corp. (FWDG)
Choom Holdings Inc. (CHOO.CN)
SIGA Technologies, Inc. (SIGA)
Business
Hester Biosciences Limited, headquartered in Ahmedabad, Gujarat, India, and founded in 1987, manufactures and markets animal healthcare products with a focus on poultry and livestock vaccines and health solutions; it operates as one of India's leading animal healthcare companies and the second-largest poultry vaccine producer in the country. The company offers an extensive portfolio spanning poultry vaccines for diseases including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, Marek's disease, infectious coryza, and fowl cholera; large animal vaccines such as goat pox, PPR from Nigerian and Sungri strains, lumpy skin disease, and classical swine fever; poultry health products encompassing medications, immune boosters, vitamin supplements, and growth promoters; animal health products for cattle including mastitis control programs; pet care solutions targeting joint disorders, gut health, and bacterial infections; and diagnostic services like seroprofiling kits and labs for poultry flocks. Hester maintains manufacturing facilities in Gujarat, India, and Nepal, alongside its subsidiary Hester Biosciences Africa Limited in Tanzania with a USD20 million investment, and extends operations to over 30 countries with emphasis on India, Nepal, Tanzania, and recent entry into Egypt. Recent developments include capacity expansions with new bulk antigen production infrastructure and a state-of-the-art fill-finish line for animal vaccines; progression toward commercialization of an updated lumpy skin disease vaccine for India in late 2025 and a low pathogenic avian influenza vaccine in Q4 2025 or Q1 2026; strategic partnerships such as with Novapharma for the Egyptian market, ongoing collaborations with Bill & Melinda Gates Foundation and GALVmed, and a tie-up with IIT Guwahati for human COVID-19 vaccine research; launch of the pet care division in 2022 with multiple products; and regulatory approvals in Tanzania for PPR and CBPP vaccines production.